Precision Breast Cancer Prevention in Norway - Experiences from the AnteNOR project

Implementation of polygenic risk score tests to improve breast cancer screening and early detection.

Every year, there are nearly 4 200 new breast cancer cases and almost 600 deaths from breast cancer in Norway, according to reports from the Norwegian Cancer Registry. Early detection is crucial for survival, but almost 40 per cent of breast cancer cases are not diagnosed at an early stage.

The AnteNOR project explores how to improve prevention and early detection of breast cancer in Norway. The project focuses on polygenic risk-score tests, a new type of technology that can provide a measure of someone’s personal risk to develop a disease.

Results and experiences from the project will be shared on 6 November, 14:00-16:30, in Jonas Einarsson Auditorium at Oslo Cancer Cluster Innovation Park. We will gather project partners, experts in the field and decision-makers to discuss how to move from research to implementation of polygenic risk score tests.

Join this seminar to learn more about the potential of polygenic risk scores and precision breast cancer prevention. Register below!

Agenda

The agenda is preliminary and may be subject to changes

13:45-14:00 Registration and coffee

14:00-14:10 Opening words
Ketil Widerberg, general manager, Oslo Cancer Cluster

14:10-14:20 AnteNOR’s contribution to the implementation of precision breast cancer prevention (in Norway). Project goals and journey.
Dr. Krista Kruuv-Käo, AnteNOR project manager, Antegenes

14:20-14:30  Performance of a breast cancer polygenic risk score in a Norwegian population
Eivind Hovig, Professor at the Centre for Bioinformatics at the University of Oslo, and group leader at Institute for Cancer Research, Oslo University Hospital

14:30-14:40 Polygenic Risk Scores and clinical presentation in sporadic cases in Norway
Denise O’Mahony, Researcher, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo

14:40-14:55 Clinical pilot study using polygenetic risk score – initial experiences
Tone Hovda, senior radiologist, Vestre Viken Hospital Trust

14:55-15:15 NETWORKING & COFFEE BREAK

15:15-15:25 Cost-effectiveness analysis of a polygenic risk-tailored breast cancer screening program in Norway
Kari Kolstad, Helseøkonom, MPhil Health Econ./Cand.pharm., Oecona AS

15:25-15:35 Cost-effectiveness analysis of a polygenic risk-tailored breast cancer screening – the BRIGHT (project) experience
Filipa Sampaio, Health economist, PhD, Uppsala County Council, Sweden

15:35-15:50 Current PRS evidence: having all the pieces of the puzzle
Peeter Padrik, CEO & founder, Antegenes

15:50-16:20 Panel discussion: From research to implementation of precision breast cancer prevention
Lovise Olaug Mæhle, overlege, Seksjon for arvelig kreft, Avdeling for medisinsk genetikk, Oslo Universitetssykehus
Peeter Padrik, CEO & founder, Antegenes
Solveig Hofvind, Head of the Mammography Programme at the Cancer Registry of Norway
Ole Alexander Opdalshei, deputy secretary general, the Norwegian Cancer Society
Moderator: Ketil Widerberg, general manager, Oslo Cancer Cluster

Project partners

Oslo Cancer Cluster, Antegenes, Oslo University Hospital, the University of Oslo and Vestre Viken.

The project is funded by EAS Enterprise Estonia.